Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 27, 2009

View Archived Issues

HSP 90 and kinase inhibitors presented by the University of Strasbourg

Novel TRPV1 receptor antagonists claimed by Renovis and Pfizer

C5aR antagonist shows promise in murine models of Alzheimer's disease

P2X7 receptor blockade improves functional recovery after SCI

Carisbamate suppresses alcohol intake in rat model of alcoholism

Johnson & Johnson develops DGAT1 inhibitors for treating the metabolic syndrome

Gefitinib derivatives in development at Concert Pharmaceuticals

Ustav Organicke Chemie a Biochemie discloses novel apoptosis inhibitors

PharmacoFore introduces novel anesthetics

Natco Pharma claims novel HER (erbB) tyrosine kinase and VEGFR inhibitors

Alpha2B- and alpha2C-adrenoceptor agonists identified at Allergan

Vertex reports results from second quarter 2009

Protalix receives FDA fast track designation for prGCD for Gaucher's disease

BioAlliance presents preliminary pivotal phase III results with acyclovir Lauriad

Lurasidone demonstrates efficacy in schizophrenia

Acorda reports FDA Advisory Committee review date for Fampridine-SR

FDA accepts Labopharm's resubmission response for novel trazodone hydrochloride formulation

Hawaii Biotech initiates phase I clinical trial for dengue vaccine

ISTA reports preliminary phase III results for once-daily Xibrom 0.09%

Morria obtains clearance to conduct phase II MRX-6 study for contact dermatitis

Adolor introduces novel cannabinoid CB2 receptor ligands as analgesics

Profectus enters research collaboration with the PATH Malaria Vaccine Initiative

Taisho and Nissan discontinue development of NT-702 for spinal canal stenosis

NovaBiotics completes phase I clinical study of Novexatin for onychomycosis

Novel antiplatelet agents presented by Astellas as potential clinical candidates

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...